Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.
NCT03402815
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
22
Enrollment
OTHER
Sponsor class
Conditions
HIV Infection With Other Conditions
Cardiovascular Risk Factor
Atherosclerosis
Inflammation
Interventions
DRUG:
Maraviroc 300 mg
Sponsor
University Of Perugia